载体选择决定了针对安哥拉马尔堡病毒的基因疫苗在非人类灵长类动物中的免疫原性和效力。
Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.
机构信息
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702-5011, USA.
出版信息
J Virol. 2010 Oct;84(19):10386-94. doi: 10.1128/JVI.00594-10. Epub 2010 Jul 21.
The immunogenicity and durability of genetic vaccines are influenced by the composition of gene inserts and choice of delivery vector. DNA vectors are a promising vaccine approach showing efficacy when combined in prime-boost regimens with recombinant protein or viral vectors, but they have shown limited comparative efficacy as a stand-alone platform in primates, due possibly to suboptimal gene expression or cell targeting. Here, regimens using DNA plasmids modified for optimal antigen expression and recombinant adenovirus (rAd) vectors, all encoding the glycoprotein (GP) gene from Angola Marburg virus (MARV), were compared for their ability to provide immune protection against lethal MARV Angola infection. Heterologous DNA-GP/rAd5-GP prime-boost and single-modality rAd5-GP, as well as the DNA-GP-only vaccine, prevented death in all vaccinated subjects after challenge with a lethal dose of MARV Angola. The DNA/DNA vaccine induced humoral responses comparable to those induced by a single inoculation with rAd5-GP, as well as CD4(+) and CD8(+) cellular immune responses, with skewing toward CD4(+) T-cell activity against MARV GP. Vaccine regimens containing rAd-GP, alone or as a boost, exhibited cellular responses with CD8(+) T-cell dominance. Across vaccine groups, CD8(+) T-cell subset dominance comprising cells exhibiting a tumor necrosis factor alpha (TNF-alpha) and gamma interferon (IFN-gamma) double-positive functional phenotype was associated with an absence or low frequency of clinical symptoms, suggesting that both the magnitude and functional phenotype of CD8(+) T cells may determine vaccine efficacy against infection by MARV Angola.
基因疫苗的免疫原性和持久性受基因插入物的组成和传递载体的选择影响。DNA 载体是一种有前途的疫苗方法,当与重组蛋白或病毒载体联合用于初次免疫-加强免疫方案时显示出疗效,但在灵长类动物中作为单一平台,其疗效有限,可能是由于基因表达或细胞靶向不理想。在这里,使用经过优化抗原表达的 DNA 质粒和重组腺病毒(rAd)载体的方案进行了比较,这些方案均编码来自安哥拉马尔堡病毒(MARV)的糖蛋白(GP)基因,以比较它们提供针对致命 MARV 安哥拉感染的免疫保护的能力。异源 DNA-GP/rAd5-GP 初次免疫-加强免疫和单一模式 rAd5-GP 以及 DNA-GP 单一疫苗,在用致死剂量的 MARV 安哥拉进行挑战后,均能预防所有接种者的死亡。DNA/DNA 疫苗诱导的体液反应可与单次接种 rAd5-GP 诱导的反应相媲美,以及 CD4(+)和 CD8(+)细胞免疫反应,并偏向针对 MARV GP 的 CD4(+)T 细胞活性。含有 rAd-GP 的疫苗方案,无论是单独使用还是作为加强剂,都表现出以 CD8(+)T 细胞为主的细胞反应。在所有疫苗组中,CD8(+)T 细胞亚群优势包括表现出肿瘤坏死因子 alpha(TNF-alpha)和伽马干扰素(IFN-gamma)双阳性功能表型的细胞,与无临床症状或低频率的临床症状相关,表明 CD8(+)T 细胞的数量和功能表型都可能决定针对 MARV 安哥拉感染的疫苗疗效。